Issuer Free Writing Prospectus

Filed Pursuant to Rule 433

Registration No. 333-221746

December 8, 2017

Akers Biosciences, Inc. Transformational Healthcare Technologies for Rapid Screening and Diagnosis 1


2 Forward Looking Statements All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Akers Biosciences, Inc. (Akers or the Company) products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward - looking statements. Any statements that are not historical fact (including, but not limited, to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward - looking statements. Forward - looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights and other risks discussed in the Company’s recent Form 10 - K and other reports filed with the Securities and Exchange Commission which are available for review at Actual results may differ materially from the results anticipated in these forward - looking statements and as such should be evaluated together with the many uncertainties that affect the Company's business. The Company disclaims any intent or obligation to update these forward - looking statements.


This presentation highlights basic information about the Company and the offering. Because it is a summary, it does not contain all of the information that you should consider before investing. This offering may only be made by means of a prospectus. Except as otherwise indicated, this presentation speaks only as of the date hereof. This presentation does not constitute an offer to sell, nor a solicitation of an offer to buy, any securities by any person in any jurisdiction in which it is unlawful for such person to make such an offering of solicitation. Neither the Securities and Exchange Commission (the ”SEC”) nor any other regulatory body has approved or disapproved of our securities or passed upon the accuracy or adequacy of this presentation. Any representation to the contrary is a criminal offense. This presentation includes industry and market data that we obtained from industry publications and journals, third - party studies and surveys, internal company studies and surveys, and other publicly available information. Industry publications generally state that the information contained therein has been obtained from sources believed to be reliable. Although we believe the industry and market data to be reliable as of the date of this presentation, this information could prove to be inaccurate. Industry and market data could be wrong because of the method by which sources obtained their data and because information cannot always be verified with complete certainty due to the limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other limitations and uncertainties. In addition, we do not know all of the assumptions that were used in preparing the forecasts from the sources relied upon or cited herein. We have filed a registration statement on Form S - 1 (including a preliminary prospectus) with the U.S. Securities and Exchange Commission (the “SEC”) for the offering to which this presentation relates. The registration statement has not yet become effective. Before you invest, you should read the preliminary prospectus in the registration statement (including the risk factors described therein) and other documents we have filed with the SEC for more complete information about the Company and the offering. You may get these documents for free by visiting EDGAR on the SEC website at Alternatively, the Company or any underwriter participating in the offering will arrange to send you the prospectus if you contact: Joseph Gunnar & Co., LLC., Prospectus Department, 30 Broad Street, 11th Floor, New York, NY 10004, telephone: (888) 248 - 6627 or email: 3 Free Writing Prospectus Statement


4 Developing and selling rapid testing technology into multi - billion dollar global markets Who we are Akers Bio is a healthcare technology company that develops and sells diagnostic tests that are fast , accurate and highly cost effective What we do Our proprietary technologies form the basis for products in three testing areas, each with significant global markets: » Clinical Diagnostics (rule - out tests and screening assays without expensive capex or lengthy turnaround times) » Speciality Retail or OTC » Health and Wellness (rapid breath testing with innovative digital and mobile technology) Why we do it » Fast, accurate tests are key to good decision - making in medicine and personal health; and also key to reducing the cost of healthcare » Our testing technologies have the capacity to transform existing testing methods in multi - billion dollar global markets


5 Experienced executive team focused on profitable growth, fiscal responsibility, and building a world class culture John J. Gormally Chief Executive Officer 39 years with global medical technology companies (Becton Dickinson, BMS, and GEM, LLC). BD Preanalytical Systems US Business Leader with $656 million in revenue and $310 million of OIBT. Has led global sales teams with up to 250 people and $1.1 billion in revenues Commercial Leader of start - up that sold for 33x earnings in 2 years Raymond F. Akers, Jr. Ph.D. Executive Chairman & Chief Scientific Director Co - founder of Akers Bio 30+ years in medical diagnostics Invented Akers Bio’s products and technologies; holds numerous patents Ph.D. in Neurochemistry, Northwestern University Gary M. Rauch, Vice President, Finance 35+ years in accounting, information systems and operations consulting Engagements in healthcare, manufacturing and distribution Douglas Carrara SR. Vice President, Global Marketing & Commercial Ops 25 years experience in sales, marketing and global operations in clinical diagnostics Held similar positions with Quest Diagnostics and Becton Dickinson Pamela E. Hibler Vice President, Sales & Distribution, North America 25+ years of success in the medical device sector, specializing in new and innovative technology Senior - level sales positions at Cogentix Medical, United States Surgical Corporation and Medical Horizons Inc.


6 Focus on Growth and Innovation Growing Product Portfolio Growing Sales and Distribution Capability Significant Global Market Potential Five products currently generating income Strong pipeline with multiple products poised for commercialization Pay - for - Performance culture New strategic partnerships Enhanced sales and marketing Strategies Point - of - care diagnostics market to reach $27.5bn by 2018 (1) Need for significant healthcare cost savings is driving demand (2) for new point - of - care tests Akers Bio competes in multi - billion (1) dollar markets of Clinical Diagnostics , Specialty Retail and Health and Wellness (1) “Point of Care Diagnostic Market Projected to Hit $27.5B by 2018” - of - care - diagnostic - market - projected - to - hit - 27 - 5b - by - 2018/ (2) “Demand for Point - of - Care Diagnostics” - for - point - of - care - diagnostics/


Technology Platform Description Product Example MPC ™ - Micro Particle Catalyzed Biosensor Permits the rapid determination of biomarkers in breath condensate PIFA ® - Particle ImmunoFiltration Assay Selective filtration of microparticles in response to antibody / antigen binding seraSTAT ® Rapid production of Serum from Whole Blood in minutes through the use of membrane technology REA ™ - Rapid Enzymatic Assay Detection of blood and urine metabolites through enzymatic chemistries in quantitative or semi - quantitative formats Company underpinned by valuable intellectual properties which form the basis for product development and licensing 7


Overview of Selected Commercialized Products 8


9 Market Opportunity Antioxidants (1) and weight loss products (2) - multi - billion dollar markets Akers Wellness products provide valuable health information in a consumer - friendly format Usage BreathScan OxiChek ™ – breath - based device providing rapid, non - invasive determination of free radical levels and the efficacy of antioxidant supplements , nutrition and exercise BreathScan KetoChek ™ – breath - based device providing rapid, non - invasive identification of optimal fat - burning state for weight loss (nutritional ketosis ) Targeted launch 1H 2018 Akers Wellness Lync TM – app - enabled, multi - device reader, providing easy, quantified personal health information via a smartphone or tablet Status Signed Aero - Med strategic partnership for selling and fulfillment Direct selling to multi - level marketing organizations Sales Channels Distribution model : • Multi - level marketing organizations • Weight loss centers • Health and fitness clubs • Anti - aging physicians Akers Digital Health / mHealth Platform Health and Wellness focused breath tests put Akers Bio at heart of multi - billion dollar market (1) “Global Antioxidants Market Expected to Reach $4.5 Billion by 2022” - news/2017 - 01 - 26/global - antioxidants - market - expected - to - reach - 45 - billion - by - 2022 / (2) “Supplement Industry Contributes $122 Billion To U.S. Economy” - exclusives/2016 - 06 - 10/supplement - industry - contributes - 122 - billion - to - us - economy


10 Akers Wellness app The app allows the user to track and monitor their health over time First diagnostic tests in the connected health and wellness market


11 Akers Wellness app Yields personalized results under 2 minutes


12 Traditional Testing (ELISA) PIFA Heparin and PIFA - PLUSS ® (Akers Bio) Equipment and Process Cap e x required Commonly outsourced No Ca pe x Performed in - house Simple Time to Results 1 to 3 DAY S’ turnaround (1) Rapid – 10 MINUTE test Faster Cost per Test (US) $150 - $300 (US) $110 - $125 Better Value Significant Related Costs ~ $1,000 to $3,000 pharmacy costs ~ $2,000 to $6,000 extended length of hospital stay None for 80%+ of patients testing negative Key Value Driver There are 4 million tests for Heparin - induced thrombocytopenia every year in the US alone using slower, traditional methods Customer Value: Potential to save a typical US hospital well over $1 Million annually Source: Warkentin Akers Bio’s rapid diagnostic tests transform traditional healthcare testing NPV >98%


Market Opportunity 4 million tests conducted annually in the US alone – all of which could be replaced with Akers Bio’s PIFA test Usage Results within 10 minutes vs. 24 - 72 hours for outsourced lab results Reduces unnecessary costs incurred with standard protocols, saving a typical U.S. hospital > $1 Million per year Status Currently selling in the US and China Agreement with Acurity (formerly Greater New York Hospital Association) Sales Channels New Go - to - Market Strategy with 3 phases of growth: 1. Value expressed in price 2. Integrated Delivery Networks 3. Awareness campaigns Sales and Marketing Structure: • Physician focus • Cardinal and Fisher: US medical device distributors • Direct sales force • Telesales partner • Internationally via in - country distribution partners • Evidence - based outcomes value proposition 13 HIT = Heparin - Induced Thrombocytopenia Source: ABI Financial The only rapid test to detect a potentially fatal allergy (HIT) to the blood thinner Heparin


14 Rapid cholesterol test selling through popular “First Check” brand in major drugstores nationwide Tri - Cholesterol “Check” The only combined rapid test for Total, HDL and LDL cholesterol Retail markets in US and EU targeted with strategic partners Selling in US under “First Check” brand (presence in major retailers incl. CVS, Rite Aid, Target, Kmart, Meijer, Giant Eagle, Stop & Shop, Giant and ShopKo) Exploring global markets including Australia , Western Europe and Asian markets


Overview of Selected Products in Development 15


16 (1) “2014 Sexually Transmitted Diseases Surveillance” (2) “Planned Parenthood at a Glance” - us/who - we - are/planned - parenthood - at - a - glance Point of care assay that delivers accurate detection of antibodies to Chlamydia in minutes Market Opportunity Most prevalent sexually transmitted disease (1) 4.7% prevalence in women aged 14 - 24 (no symptoms in women) (2) >4 million tests annually at Planned Parenthood Approximately 3.4 million cases go undiagnosed Usage Single - use device based on PIFA technology Simple test using whole blood Results within 5 minutes vs. 24 - 72 hours for outsourced lab results Status Clinical trials highly successful Under FDA review (Submitted May 2017) Sales Channels Target markets include but are not limited to: 1. Planned Parenthood 2. Ambulatory care, clinics, urgent care and Federally Qualified Health Clinics 3. US Government 4. College campus clinics Value Driver • Focus on Turnaround Time – achieving diagnosis and, if necessary, prescribing treatment prior to patient leaving facility (unlike existing formats) • Accuracy • Reimbursement


Market Size LUNG CANCER : > 1.6 million people worldwide diagnosed annually ASTHMA : 300 million people worldwide diagnosed; prevalence up to 18% COPD : 210 million people currently in treatment; up to 1 billion smokers at risk Usage Single - use, non - invasive device for pulmonary health screenings with the capacity to dramatically change the speed and cost of diagnosing major respiratory conditions Status Asthma clinical trials highly successful Next Steps File 510(k) for FDA clearance. In order of filing: Asthma, COPD, Lung Cancer Seek distribution as companion diagnostics with prescription medicines; partner with primary care - based diagnostic sales organizations and distributors that market to retail health clinics 17 Breath PulmoHealth Breath tests for biomarkers indicating Lung Cancer, Asthma and COPD Source: ABI Financial 2019


18 Multiple rapid tests are being developed , targeting large diagnostic markets Targeting 201 8 Launch Targeting 201 9 Launch • PIFA Chlamydia (submitted FDA 510(k)) • BreathScan KetoChek ™ • BreathScan pH (Asthma) • BreathScan PulmoHealth (COPD) • BreathScan PulmoHealth (lung cancer) • Heart attack test • BreathScan THC • BreathScan DKA (diabetic ketoacidosis)


2017 revenues tracking 10% over FY 2016 19 201 6 Full Year 9M to Sep 30, 2017 Revenue: - PIFA & PIFA Associated Products $2,577,148 *$1,977,726 - MPC Biosensor Products $282,516 $381.569 - REA Products - 27,500 - Other Products $97,498 $116,647 - License & Service Revenue $3,750 $37,500 Total Revenue: $2,960,912 $2,540,942 Gross Profit: $1,877,825 $1,694,455 Operating Expenses: - General & Administrative $3,008,811 **$2,440,023 - Sales & Marketing $2,137,282 $1,382,416 - Research & Development $1,188,868 $952,724 (Reversal of Allowance) for Bad Debt $(1,299,609) - Net Los s Attributable to Shareholders: $(3,303,538) $(3,193,571) Basic & Diluted ( Loss ) Per Common Share $(0.61) $(0.39) *Includes $500,000 of PIFA - associated products shown as “Other Products” in the Form 10 - Q **Approximately $243,000 of G&A expenses incurred in 9M 2017 were in respect of extraordinary legal expenses


As of Dec 31 , 2016 Sep 30, 2017 Total Assets $ 5,085,107 $ 5,528,333 Cash & Marketable Securities $ 122,701 *$145,311 Total Liabilities $1,697,430 $1,581,792 Total Equity $ 3,387,677 $ 3,946,541 20 Balance sheet no commercial debt *Cash & Marketable Securities boosted after quarter - end following receipt of $680,748 in net proceeds from the conversion of warrants during Oct 2017


Capitalization as of December 7, 2017 Common stock 9,920,551 Options (weighted average exercise price $4.25) 255,000 Warrants (weighted average exercise price $1.39) 1,490,570 Company capitalization 22


Clear path to grow value High margin, niche tests Blockbuster potential Moving towards profitability Enhanced sales and distribution Launch new rapid tests Develop new rapid test s a: 201 Grove Road, Thorofare , N.J. 08086, USA t: +1 (856) 848 8698 e: tw : @ AkersBio 23